Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Immunotherapy

Unique CDR3 epitope targeting by CAR-T cells is a viable approach for treating T-cell malignancies

A Correction to this article was published on 16 May 2019

This article has been updated

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2

Change history

  • 16 May 2019

    In the original version of this article the author name Xiaolei Chen was published incorrectly. This has been corrected to Xiao Lei Chen.

References

  1. 1.

    Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;2016:12.

    Google Scholar 

  2. 2.

    Guru Murthy GS, Dhakal I, Mehta P. Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States. Leuk Lymphoma. 2017;58:1648–54.

    Article  Google Scholar 

  3. 3.

    Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2016;2016:580–8.

    Article  Google Scholar 

  4. 4.

    Pinz KG, Yakaboski E, Jares A, Liu H, Firor AE, Chen KH, et al. Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells. Oncotarget. 2017;8:112783–96.

    Article  Google Scholar 

  5. 5.

    Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015;126:983–92.

    CAS  Article  Google Scholar 

  6. 6.

    Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, et al. Targeting the T-cell receptor beta-chain constant region for immunotherapy of T-cell malignancies. Nat Med. 2017;23:1416–23.

    CAS  Article  Google Scholar 

  7. 7.

    Perera LP, Zhang M, Nakagawa M, Petrus MN, Maeda M, Kadin ME, et al. Chimeric antigen receptor modified T-cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies. Am J Hematol. 2017;92:892–901.

    CAS  Article  Google Scholar 

  8. 8.

    Gong Q, Wang C, Zhang W, Iqbal J, Hu Y, Greiner TC, et al. Assessment of T-cell receptor repertoire and clonal expansion in peripheral T-cell lymphoma using RNA-seq data. Sci Rep. 2017;7:11301.

    Article  Google Scholar 

  9. 9.

    Ruggiero E, Nicolay JP, Fronza R, Arens A, Paruzynski A, Nowrouzi A, et al. High-resolution analysis of the human T-cell receptor repertoire. Nat Commun. 2015;6:8081.

    Article  Google Scholar 

  10. 10.

    de Leval L, Bisig B, Thielen C, Boniver J, Gaulard P. Molecular classification of T-cell lymphomas. Crit Rev Oncol Hematol. 2009;72:125–43.

    Article  Google Scholar 

  11. 11.

    Bertness V, Kirsch I, Hollis G, Johnson B, Bunn PA Jr. T-cell receptor gene rearrangements as clinical markers of human T-cell lymphomas. N Engl J Med. 1985;313:534–8.

    CAS  Article  Google Scholar 

  12. 12.

    Assaf C, Hummel M, Steinhoff M, Geilen CC, Orawa H, Stein H, et al. Early TCR-beta and TCR-gamma PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications. Blood. 2005;105:503–10.

    CAS  Article  Google Scholar 

  13. 13.

    Wu D, Sherwood A, Fromm JR, Winter SS, Dunsmore KP, Loh ML, et al. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med. 2012;4:134ra163.

    Article  Google Scholar 

  14. 14.

    Yadav M, Delamarre L. IMMUNOTHERAPY. Outsourcing the immune response to cancer. Science. 2016;352:1275–6.

    CAS  Article  Google Scholar 

  15. 15.

    Iurescia S, Fioretti D, Pierimarchi P, Signori E, Zonfrillo M, Tonon G, et al. Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma. J Biomed Biotechnol. 2010;2010:316069.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by the Fujian Provincial Natural Science Foundation 2016S016 China and Putian city Natural Science Foundation 2014S06(2), Fujian Province, China. Alexey Stepanov and Alexander Gabibov were supported by Russian Scientific Foundation project No. 17-74-30019. Jinqi Huang was supported by a doctoral fellowship from Xiamen University, China.

Author Contributions

JH, SA, JL, GF, XC, and CMT designed the study; JH, SA, JL, JXJZ, and XX performed and analyzed the experiments; JH, DC, and XW contributed to patient clinical care and data collection; JX and GF provided scientific advice; TJ, GG, and LD proof read the manuscript, JH, SA, JL, GF, MM, AG, JX, and CMT wrote the paper; and all authors read and approved the final version of the manuscript.

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Xiao Lei Chen, Guo Fu, Gabibov Alexander or Chi-Meng Tzeng.

Ethics declarations

Conflict of interest:

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Huang, J., Alexey, S., Li, J. et al. Unique CDR3 epitope targeting by CAR-T cells is a viable approach for treating T-cell malignancies. Leukemia 33, 2315–2319 (2019). https://doi.org/10.1038/s41375-019-0455-3

Download citation

Further reading

Search

Quick links